OSTEOGENESIS IMPERFECTA TREATMENT MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2025-2032)

Osteogenesis imperfect, or OI, is a genetic disorder that affects the bones and also prevents the body from building strong bones. This disease makes the bones brittle and breaks easily without any cause. OI is referred to as imperfect bone formation, and people suffering from this disorder have bones that fracture or break easily. Therefore, this condition is also commonly known as brittle bone disease. In severe OI cases, multiple fractures are common, whereas a milder case involves a few fractures or bone breaks in a person's lifetime. People with this condition are either born unable to produce connective tissue or have it due to faulty genes. It has an impact on the synthesis of collagen, the connective tissue protein that strengthens bones. The illness comes in I and IX forms, with I being mild and IX being fatal. The major sign of osteogenesis imperfecta is frequent fractures. Other symptoms include loose joints, deformed bones, loss of hearing, breathing issues, and tooth problems. Osteogenesis imperfecta can be confirmed through DNA or collagen testing. There is no treatment for it because it is a genetic condition. Exercise and giving up smoking are two examples of healthy lifestyle choices that can help prevent fractures. Braces, painkillers, and correct bone fracture care are all beneficial. Antibiotics and antiseptics can be used to treat bone infections. Rising demand for novel therapies for osteogenesis imperfecta treatment and licensing agreements and strategic collaborations by key industry players for the development of OI treatment are expected to propel the growth of global osteogenesis imperfecta treatment market over the forecast period.

Market Dynamics

The surge in funding for research & development to develop novel treatment and therapies is a major factor boosting growth of the global osteogenesis imperfecta treatment market. Moreover, licensing agreements and strategic collaborations by key industry players for the development of OI treatment is another factor propelling the market growth. Moreover, osteogenesis imperfecta is a genetic disorder and the family history of people with OI is resulting in rising number of cases across the globe, which is expected to drive the market growth. For instance, in May 2021, Mereo BioPharma Group plc announced encouraging 6-month data from its phase II-B clinical study in adult patients with Type IV, III, or I osteogenesis imperfecta treated with setursumab (BPS-804). The European Medicines Agency (EMA) had approved the company’s pediatric investigation plan for BPS-804 and with a registration study design, and the drug candidate is now phase III ready for a pediatric population.

Key features of the study:

• This report provides in-depth analysis of the global osteogenesis imperfecta treatment market, and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR%) for the forecast period 2025-2032, considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global osteogenesis imperfecta treatment market based on the following parameters– company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study are BioSenic SA, Mereo Biopharma Group PLC, CELGENE CORPORATION, Eli Lilly and Company, Cipla Inc., Amgen Inc., Sun Pharmaceutical Industries Ltd., Viatris Inc., Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., Jubilant Pharmova Limited, Aurobindo Pharma, Quince, Ultragenyx Pharmaceutical Inc. and OrthoPediatrics Corp.
• Insights from this report will allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global osteogenesis imperfecta treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global osteogenesis imperfecta treatment market

Detailed Segmentation:

• Global Osteogenesis Imperfecta Treatment Market, By Drugs:
  • Teriparatide
  • Denosumab
  • Others
• Global Osteogenesis Imperfecta Treatment Market, By Route of Administration:
  • Subcutaneous
  • Intravenous
  • Oral
  • Others
• Global Osteogenesis Imperfecta Treatment Market, By Region:
  • North America
    
    • U.S.
    • Canada
  • Latin America
    
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    
    • South Africa
    • Central Africa
    • North Africa
• Company Profiles
  • BioSenic SA 
  • Mereo Biopharma Group PLC
  • CELGENE CORPORATION
  • Eli Lilly and Company
  • Cipla Inc.
  • Amgen Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Merck & Co., Inc.
  • Jubilant Pharmova Limited
  • Aurobindo Pharma
  • Quince
  • Ultragenyx Pharmaceutical Inc.
  • OrthoPediatrics Corp.